Related Experiment Video
Updated: May 15, 2026

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results
Vijaya Raj Bhatt1, Hagop Kantarjian, Jorge E Cortes
1Leukemia Department, MD Anderson Cancer Center, Houston, TX 77030, USA.
Unlabelled:
Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor AML leaves room for substantial improvement. We discuss treatments that have improved outcome in this group of patients with AML and ongoing/future strategies that might contribute toward incremental gains.
Background:
Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement.
Materials And Methods:
We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts.
Results:
Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer.
Conclusions:
Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Differentiation of Common Myeloid Progenitor Cells
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
